{"downloaded": true, "htmlmade": false, "full": {"id": "30548250", "source": "MED", "pmid": "30548250", "pmcid": "PMC7771320", "fullTextIdList": {"fullTextId": "PMC7771320"}, "doi": "10.1111/bjh.15700", "title": "Lenalidomide-based response-adapted therapy for older adults without high risk myeloma.", "authorString": "Baz R, Naqvi SMH, Lee JH, Brayer J, Hillgruber N, Fridley BL, Shain KH, Sullivan DM, Alsina M.", "authorList": {"author": [{"fullName": "Baz R", "firstName": "Rachid", "lastName": "Baz", "initials": "R", "authorId": {"@type": "ORCID", "#text": "0000-0003-4538-4733"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Malignant Haematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA."}}}, {"fullName": "Naqvi SMH", "firstName": "Syeda Mahrukh Hussnain", "lastName": "Naqvi", "initials": "SMH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA."}}}, {"fullName": "Lee JH", "firstName": "Jae-Hoon", "lastName": "Lee", "initials": "JH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Hematology, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea."}}}, {"fullName": "Brayer J", "firstName": "Jason", "lastName": "Brayer", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Malignant Haematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA."}}}, {"fullName": "Hillgruber N", "firstName": "Nancy", "lastName": "Hillgruber", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Malignant Haematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA."}}}, {"fullName": "Fridley BL", "firstName": "Brooke L", "lastName": "Fridley", "initials": "BL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Biostatistics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA."}}}, {"fullName": "Shain KH", "firstName": "Kenneth H", "lastName": "Shain", "initials": "KH", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Malignant Haematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA."}}}, {"fullName": "Sullivan DM", "firstName": "Daniel M", "lastName": "Sullivan", "initials": "DM", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA."}}}, {"fullName": "Alsina M", "firstName": "Melissa", "lastName": "Alsina", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA."}}}]}, "authorIdList": {"authorId": {"@type": "ORCID", "#text": "0000-0003-4538-4733"}}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "5", "volume": "184", "journalIssueId": "2783705", "dateOfPublication": "2019 Mar", "monthOfPublication": "3", "yearOfPublication": "2019", "printPublicationDate": "2019-03-01", "journal": {"title": "British journal of haematology", "ISOAbbreviation": "Br J Haematol", "medlineAbbreviation": "Br J Haematol", "NLMid": "0372544", "ISSN": "0007-1048", "ESSN": "1365-2141"}}, "pubYear": "2019", "pageInfo": "735-743", "abstractText": "Combined lenalidomide and dexamethasone is a standard-of-care therapy for the treatment of older adults with multiple myeloma. Lenalidomide monotherapy has not been evaluated in newly diagnosed myeloma patients. We conducted a phase II study, evaluating a response-adapted therapy for older adults newly diagnosed with multiple myeloma without high-risk features who were ineligible for high-dose therapy and stem cell transplant. Patients were started on single-agent lenalidomide, and low-dose dexamethasone was added in the event of progressive disease, in a response-adapted approach. The primary endpoint was progression-free survival (PFS), and the International Myeloma Working Group's uniform response criteria were used to assess response and progression. Twenty-seven patients were enrolled, and 20 (74%) experienced a partial response or better to this response-adapted therapy. After a median follow-up of 69\u00a0months, the median PFS was 36\u00a0months [95% confidence interval (CI), 29\u00b78 to not reached], and the median overall survival was 65\u00a0months (95% CI, 35\u00b73 to not reached). Grade 3/4 adverse events were mainly haematological in nature. This response-adapted therapy in this patient population is feasible and results in durable responses that compare favourably with concurrent lenalidomide and dexamethasone. These results should be validated in prospective studies.", "affiliation": "Department of Malignant Haematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.", "publicationStatus": "ppublish", "language": "eng", "pubModel": "Print-Electronic", "pubTypeList": {"pubType": ["Comparative Study", "Clinical Trial", "Research Support, Non-U.S. Gov't", "research-article", "Journal Article"]}, "grantsList": {"grant": {"grantId": "P30 CA076292", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Multiple Myeloma", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Disease-Free Survival"}, {"majorTopic_YN": "N", "descriptorName": "Survival Rate"}, {"majorTopic_YN": "N", "descriptorName": "Risk Factors"}, {"majorTopic_YN": "N", "descriptorName": "Follow-Up Studies"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}, {"majorTopic_YN": "N", "descriptorName": "Lenalidomide", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "Y"}}}]}, "keywordList": {"keyword": ["myeloma", "Older Adults", "Lenalidomide", "Response-adapted Therapy"]}, "chemicalList": {"chemical": {"name": "lenalidomide", "registryNumber": "F0P408N6V4"}}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1111/bjh.15700"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7771320"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC7771320?pdf=render"}, {"availability": "Free", "availabilityCode": "F", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1111/bjh.15700"}]}, "isOpenAccess": "N", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "N", "citedByCount": "0", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "authMan": "Y", "epmcAuthMan": "N", "nihAuthMan": "Y", "manuscriptId": "NIHMS1654486", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-12-30", "dateOfCreation": "2018-12-15", "firstIndexDate": "2018-12-21", "fullTextReceivedDate": "2020-12-31", "dateOfRevision": "2020-12-30", "electronicPublicationDate": "2018-12-12", "firstPublicationDate": "2018-12-12"}, "abstract": "Combined lenalidomide and dexamethasone is a standard-of-care therapy for the treatment of older adults with multiple myeloma. Lenalidomide monotherapy has not been evaluated in newly diagnosed myeloma patients. We conducted a phase II study, evaluating a response-adapted therapy for older adults newly diagnosed with multiple myeloma without high-risk features who were ineligible for high-dose therapy and stem cell transplant. Patients were started on single-agent lenalidomide, and low-dose dexamethasone was added in the event of progressive disease, in a response-adapted approach. The primary endpoint was progression-free survival (PFS), and the International Myeloma Working Group's uniform response criteria were used to assess response and progression. Twenty-seven patients were enrolled, and 20 (74%) experienced a partial response or better to this response-adapted therapy. After a median follow-up of 69\u00a0months, the median PFS was 36\u00a0months [95% confidence interval (CI), 29\u00b78 to not reached], and the median overall survival was 65\u00a0months (95% CI, 35\u00b73 to not reached). Grade 3/4 adverse events were mainly haematological in nature. This response-adapted therapy in this patient population is feasible and results in durable responses that compare favourably with concurrent lenalidomide and dexamethasone. These results should be validated in prospective studies.", "Keywords": ["myeloma", "Older Adults", "Lenalidomide", "Response-adapted Therapy"], "journaltitle": "British journal of haematology", "authorinfo": ["Baz R", "Naqvi SMH", "Lee JH", "Brayer J", "Hillgruber N", "Fridley BL", "Shain KH", "Sullivan DM", "Alsina M"], "title": "Lenalidomide-based response-adapted therapy for older adults without high risk myeloma."}